{
    "nctId": "NCT03872141",
    "briefTitle": "Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients",
    "officialTitle": "Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Chemotherapy Induced Peripheral Neuropathy, Paclitaxel Induced Neuropathy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Verbal Memory Test",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women ages 18 to 70 with histologically confirmed clinically stage I-III breast cancer who will receive weekly paclitaxel (80 mg/m2) or docetaxel (60-100mg/m2) chemotherapy as part of their routine care.\n\nExclusion Criteria:\n\n* diabetes mellitus\n* prior history of neuropathy or symptoms of numbness or peripheral pain, or prior neurotoxic chemotherapy.\n* current symptoms of numbness and neuropathic pain\n* treatment for bipolar disease\n* treatment or concomitant use of common medications used to treat neuropathic pain, such as amitriptyline, gabapentin, pregabalin, duloxetine, for any indication\n* limited English that would preclude understanding and completion of the study questionnaires\n* pregnancy\n* life expectancy \\<12 weeks\n* participation in other research studies either concurrent with or within 30 days prior to participation in this study may be an exclusion criteria",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}